IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Time to Sell?

IPSEN (OTCMKTS:IPSEY) gapped down prior to trading on Tuesday . The stock had previously closed at $46.75, but opened at $43.61. IPSEN shares last traded at $43.61, with a volume of 300 shares changing hands.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IPSEY. HC Wainwright began coverage on shares of IPSEN in a research report on Friday, June 5th. They issued a “buy” rating on the stock. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, IPSEN currently has a consensus rating of “Hold”.

IPSEN Price Performance

The stock’s 50-day moving average price is $47.78 and its 200-day moving average price is $43.24.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).